James J. Harding, MD
Gastrointestinal Cancers; Liver Cancer (Hepatocellular Carcinoma); Bile Duct Cancers (Cholangiocarcinoma); Gallbladder Cancers; Fibrolamellar Carcinoma; Early Drug Development; Immunotherapy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Harding accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Albert Einstein College of Medicine
Internal Medicine - NewYork-Presbyterian Hospital
Oncology/Hematology - Memorial Sloan Kettering Cancer Center
Internal Medicine; Medical Oncology
I am a board-certified medical oncologist who specializes in caring for people with liver cancer, gallbladder cancer, and bile duct cancer, as well as other gastrointestinal cancers. My primary goal is to provide the best possible treatment and individualized care for people with these diseases. I work closely with a team of surgeons, radiation oncologists, and other medical professionals who specialize in the diagnosis and treatment of gastrointestinal cancer.
In my research, I am trying to find new, effective therapies for gastrointestinal cancer, particularly primary liver and bile duct tumors. For example, I am working on ways to use a patient’s own immune system to fight cancer, which is called immunotherapy. In addition, I am investigating strategies to block specific cellular pathways that cancer uses to grow. I have developed and am leading numerous national and international clinical trials of these new cancer therapies for patients with liver, bile duct cancers, and other solid tumors.
I am also focused on improving how we conduct clinical research with patients and increasing access to clinical trials. To this aim, I am a standing member of the Institutional Review Board, which is the committee that approves all clinical research at Memorial Sloan Kettering. I am also part of several other executive committees aimed at improving the conduct of clinical trials.
My research and training has been supported by the American Society of Clinical Oncology, the National Comprehensive Cancer Network, the National Institutes of Health, the American Association for Cancer Research, and the Howard Hughes Medical Institute. My work has been published in the New England Journal of Medicine, Nature, Nature Medicine, the Journal of Clinical Oncology, Cancer Discovery, Clinical Cancer Research, and Cancer.
- Clinical Trials Investigated by Dr. Harding
- A Phase I Study of BI 905711 in People with Advanced Digestive Cancers
- A Phase I Study of LY3410738 in Patients with Advanced Solid Tumors with IDH1 Mutations
- A Phase II Study to Compare YIV-906 plus Sorafenib versus Sorafenib Alone in Patients with Liver Cancer Who Also Have Hepatitis B
- A Phase IIB Study of ZW25 in People with Advanced HER2-Positive Biliary Tract Cancers
- A Study Assessing Nivolumab Immunotherapy Added to Chemoembolization for Liver Cancer
- Clinical Trials Co-Investigated by Dr. Harding
- A Phase I Study of AZD1390 plus Radiation Therapy in Patients with Glioblastoma Multiforme or Brain Metastases
- A Phase I Study of BI 905677 in Patients with Advanced Solid Tumors
- A Phase I Study of RLY-4008 for Intrahepatic Cholangiocarcinoma and Other Advanced Solid Tumors
- A Phase II Study of Erdafitinib in Patients Whose Tumors Have an FGFR Alteration
- A Phase II Study of Trastuzumab Deruxtecan in People with HER2-Positive Solid Tumors
- A Study of Derazantinib in People with Inoperable or Advanced Intrahepatic Cholangiocarcinoma and FGFR2-Related Genetic Changes
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Visit PubMed for a full listing of Dr. Harding’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James J. Harding discloses the following relationships and financial interests:
Provision of Services
MORE Health, Inc
Provision of Services
Merck & Co Inc.
Provision of Services
QED Therapeutics, Inc.
Provision of Services
Research to Practice
Provision of Services
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.